Posted on 22/06/2010 in Pharmaceutical Company Financials Grifols president Victor Grifols has underlined the progress made by the pharmaceutical company during 2009.
Speaking at Grifols' annual general meeting, Mr Grifols praised the firm's "sound" financial performance during the last 12 months, with revenues across all divisions achieving high levels during the four quarters of 2009.
He also highlighted the fact that it has been able to achieve cost reductions without an accompanying decrease in investment or research and development expenditure, thereby safeguarding its long-term growth.
Mr Grifols states that the firm has been able to convince banks and investors that it remains poised for future growth.
He concluded: "The achievements of 2009 are the result of a sound ethical, practical and legal philosophy that guarantees growth and enables the search for opportunities."
Earlier this month, Grifols announced that it will be acquiring Talecris Biotherapeutics, a move which Mr Grifols stated will strengthen its research capabilities and its ability to meet patient needs.Other news stories from 22/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
